Explore how AI-native Electronic Lab Notebooks convert record-keeping into proactive research assistance, integrating tools and data to accelerate drug discovery.
AI-Native ELNs: How Intelligent Lab Notebooks Speed Drug Discovery Read More »
Latest on Verily’s $300M raise, Latent Labs’ Latent-X2, Insilico’s PandaClaw, and BMS-insitro ALS work. What these moves mean for AI-driven drug discovery.
AI Drug Discovery’s Momentum: Key Updates from the Frontier Read More »
EMA and FDA publish joint principles for safe AI across the medicines lifecycle, guiding risk-based validation, data governance, human oversight and patient safety.
Global Standards for AI in Drug Discovery: EMA and FDA Principles Read More »
A concise overview of Europe’s AI-driven drug discovery market: market trajectory, key technologies, leading countries, main challenges, and strategic opportunities.
Europe’s AI Drug Discovery Surge: Trends, Players, and What’s Next Read More »
How pharma can convert fragmented legacy data into a living scientific memory to accelerate AI-driven drug discovery and secure lasting competitive advantage.
AI Drug Discovery’s Hidden Power: Transforming Legacy Data into Living Scientific Memory Read More »
AI in drug discovery is set to grow 25-30% over five years. Read a concise briefing on drivers, key applications like oncology, major innovations and remaining hurdles.
AI in Drug Discovery: Trends, Partnerships and the Road Ahead Read More »
Merck teams with Mayo Clinic to combine Mayo Clinic Platform data and Merck’s AI virtual cell tools to speed AI-driven drug discovery for IBD, atopic dermatitis and MS.
Merck and Mayo Clinic Partner to Accelerate AI Drug Discovery Read More »
Major pharma firms are realizing real ROI from AI now — through faster R&D workflows, smarter trials, and commercial and administrative savings rather than headline drug discoveries.
AI’s Immediate Impact on Pharma: Operational Wins That Matter Today Read More »
Generative AI is reshaping drug discovery by predicting protein structures, designing antibodies, and making GPCRs targetable. Learn how GenAI shortens timelines and opens new therapies.
GenAI’s Breakthrough in Drug Discovery: Drugging GPCRs and Other Undruggable Targets Read More »
Insilico Medicine and Qilu Pharmaceutical launched a strategic collaboration using Chemistry42 and Biology42 to discover cardiometabolic drug candidates. Read a concise analysis of what this deal means for AI adoption in pharma.
